ERBB2 and uterine carcinosarcoma: A more recent clinical study using an optimized HER2-targeted antibody-drug conjugate (trastuzumab deruxtecan) in patients with HER2 (encoded by ERBB2) immunohistochemistry high (2+ or 3+) and low (1+) uterine carcinosarcoma found clinical efficacy in both HER2-high and -low groups [32].